Tarsus Pharmaceuticals Achieves $15M Milestone Payment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 23 2026
0mins
Should l Buy TARS?
Tarsus Pharmaceuticals announced that a $15M milestone payment due Tarsus has been achieved following regulatory approval of TP-03, or lotilaner ophthalmic solution, 0.25% by the National Medical Products Administration of the People's Republic of China. "TP-03 is once again the first and only therapy approved to address the root cause of Demodex blepharitis - marking a meaningful advance for the more than 40 million people in the region affected by this disease," said Bobak Azamian, chairman and CEO of Tarsus. The approval was obtained by Grand Pharmaceutical Group Limited, Tarsus' exclusive partner for the development and commercialization of TP-03 for the treatment of Demodex blepharitis in the Greater China region. Under the terms of the agreement with Grand Pharma, Tarsus is eligible to receive the $15M milestone payment based on regulatory approval in China and patent issuance related to TP-03, both conditions of which have been achieved.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TARS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TARS
Wall Street analysts forecast TARS stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 70.220
Low
68.00
Averages
89.33
High
100.00
Current: 70.220
Low
68.00
Averages
89.33
High
100.00
About TARS
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tarsus Initiates Clinical Trial for Lyme Disease Prevention
- Trial Launch: Tarsus Pharmaceuticals announced the dosing of the first participant in its Phase 2 clinical trial, Calliope, evaluating the novel oral therapy TP-05 (lotilaner) designed to kill Lyme-infected ticks before disease transmission, with enrollment expected to complete during the 2026 tick season and topline results anticipated in the first half of 2027.
- Urgent Market Need: Recent market research indicates that over 35 million Americans are at moderate to high risk for Lyme disease, with approximately 300,000 to 400,000 diagnosed annually, highlighting the critical demand for new prophylactic measures, especially as climate change expands the geographic range of ticks.
- Significant Efficacy: In the Phase 2a Carpo trial, TP-05 demonstrated over 90% tick mortality within 24 hours of attachment, compared to only 5% in the placebo group (p<0.001), indicating its potential in preventing Lyme disease transmission while showing good tolerability.
- Strategic Implications: TP-05 is considered the only non-vaccine drug-based prophylactic in development, and if approved by the FDA, it could fundamentally shift Lyme disease management from treatment to prevention, significantly reducing infection risks and improving public health outcomes.
See More
Tarsus Pharmaceuticals Executive Sells Shares Amid Strong Sales Growth
- Executive Stock Sale: Dianne C. Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals, sold 12,274 shares of common stock between March 17 and 19, 2026, for approximately $839,000, indicating her ongoing pattern of reducing holdings.
- Shareholding Reduction: This transaction reduced Whitfield's direct holdings from 47,302 shares to 35,028 shares, representing a 25.95% decrease, reflecting her strategy of gradual divestment in line with available share capacity.
- Market Performance Analysis: Tarsus Pharmaceuticals generated $451.4 million in net product sales in 2025, more than doubling from the previous year, although the company remains unprofitable with a narrowed net loss of $66.4 million, showcasing strong unit economics.
- Future Growth Prospects: The company is advancing multiple clinical trials, including indications for ocular rosacea and Lyme disease prevention, with several Phase 2 catalysts on the horizon, indicating potential growth drivers for its product pipeline.
See More
Tarsus Pharmaceuticals Executive Sells Shares for Tax Obligations
- Executive Stock Sale: Dianne C. Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals, sold 12,274 shares between March 17 and March 19, 2026, for approximately $839,000 at an average price of $68.36 per share, indicating a non-discretionary sale driven by tax obligations.
- Clear Purpose of Sale: The stock sale was conducted to cover tax withholding obligations, and as disclosed in SEC Form 4, it involved only direct ownership with no indirect entities or derivative securities reported, suggesting that this transaction does not reflect changes in the company's fundamentals.
- Strong Financial Performance: Tarsus Pharmaceuticals generated $451.4 million in net product sales in 2025, more than doubling from the previous year, with fourth-quarter sales reaching $151.7 million and gross margins around 93%, demonstrating robust unit economics.
- Future Growth Potential: Although the company remains unprofitable, the net loss narrowed to $66.4 million for 2025, and it ended the year with over $417 million in cash and marketable securities, providing runway for pipeline expansion, with management advancing multiple Phase 2 trials for indications like ocular rosacea and Lyme prevention.
See More
TARSUS PHARMACEUTICALS INC - QUALIFIED FOR EXTRA MILESTONES AND GRADUATED ROYALTIES FOR TP-03 IN GREATER CHINA
- Company Announcement: Tarsus Pharmaceuticals has announced eligibility for additional milestones and tiered royalties related to their product TP-03 in Greater China.
- Market Expansion: This development indicates Tarsus's strategic efforts to expand its market presence and capitalize on opportunities in the Chinese pharmaceutical sector.
See More
Tarsus Pharmaceuticals Q4 2025 Earnings Call Highlights
- Sales Performance Breakthrough: Tarsus Pharmaceuticals achieved over $450 million in net sales for 2025, successfully aiding more than 500,000 patients with Demodex blepharitis, indicating strong market demand for its product XDEMVY, which is expected to drive sustained growth for the company.
- Future Growth Potential: Management anticipates that XDEMVY's sales potential will exceed $2 billion, reflecting confidence in market penetration and the expansion of the prescriber base, strategically laying the groundwork for future revenue growth.
- R&D and Clinical Trials: Tarsus initiated the first-ever Phase II trial for TP-04 targeting ocular rosacea and plans to conduct a clinical trial for TP-05 in 2026, demonstrating the company's proactive approach to new product development and market expansion.
- Financial Outlook: The guidance for 2026 net product sales is projected between $670 million and $700 million, with annual growth exceeding $230 million, as management maintains an optimistic view on future sales growth while expecting operating expenses to remain within a reasonable range to ensure financial health.
See More
Tarsus Pharmaceuticals Reports Narrowed Losses in 2025 Financials
- Significant Sales Growth: In Q4 2025, Tarsus Pharmaceuticals reported net product sales of $151.67 million, a 128% increase from $66.41 million in the same quarter last year, indicating strong market demand for its core product XDEMVY, which significantly boosts company revenue.
- Narrowed Losses: The net loss for Q4 2025 was $8.37 million, or $0.20 per share, a substantial improvement from a loss of $23.11 million and $0.60 per share in the prior year, reflecting effective strategies in cost control and sales growth.
- Global Expansion Plans: XDEMVY is expected to receive approval for a preservative-free formulation in Europe by 2027, while its partner Grand Pharmaceutical Group Ltd. anticipates approval in Greater China by 2026, which will further enhance the company's growth potential in international markets.
- R&D Drug Progress: The company is conducting clinical trials for TP-04 and TP-05, with the former targeting ocular rosacea and the latter aimed at Lyme disease prevention, with TP-05 expected to initiate studies in Q2 2026, providing new growth opportunities for the company's future product pipeline.
See More
Tarsus Initiates Clinical Trial for Lyme Disease Prevention
- Trial Launch: Tarsus Pharmaceuticals announced the dosing of the first participant in its Phase 2 clinical trial, Calliope, evaluating the novel oral therapy TP-05 (lotilaner) designed to kill Lyme-infected ticks before disease transmission, with enrollment expected to complete during the 2026 tick season and topline results anticipated in the first half of 2027.
- Urgent Market Need: Recent market research indicates that over 35 million Americans are at moderate to high risk for Lyme disease, with approximately 300,000 to 400,000 diagnosed annually, highlighting the critical demand for new prophylactic measures, especially as climate change expands the geographic range of ticks.
- Significant Efficacy: In the Phase 2a Carpo trial, TP-05 demonstrated over 90% tick mortality within 24 hours of attachment, compared to only 5% in the placebo group (p<0.001), indicating its potential in preventing Lyme disease transmission while showing good tolerability.
- Strategic Implications: TP-05 is considered the only non-vaccine drug-based prophylactic in development, and if approved by the FDA, it could fundamentally shift Lyme disease management from treatment to prevention, significantly reducing infection risks and improving public health outcomes.
See More
Tarsus Pharmaceuticals Executive Sells Shares Amid Strong Sales Growth
- Executive Stock Sale: Dianne C. Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals, sold 12,274 shares of common stock between March 17 and 19, 2026, for approximately $839,000, indicating her ongoing pattern of reducing holdings.
- Shareholding Reduction: This transaction reduced Whitfield's direct holdings from 47,302 shares to 35,028 shares, representing a 25.95% decrease, reflecting her strategy of gradual divestment in line with available share capacity.
- Market Performance Analysis: Tarsus Pharmaceuticals generated $451.4 million in net product sales in 2025, more than doubling from the previous year, although the company remains unprofitable with a narrowed net loss of $66.4 million, showcasing strong unit economics.
- Future Growth Prospects: The company is advancing multiple clinical trials, including indications for ocular rosacea and Lyme disease prevention, with several Phase 2 catalysts on the horizon, indicating potential growth drivers for its product pipeline.
See More
Tarsus Pharmaceuticals Executive Sells Shares for Tax Obligations
- Executive Stock Sale: Dianne C. Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals, sold 12,274 shares between March 17 and March 19, 2026, for approximately $839,000 at an average price of $68.36 per share, indicating a non-discretionary sale driven by tax obligations.
- Clear Purpose of Sale: The stock sale was conducted to cover tax withholding obligations, and as disclosed in SEC Form 4, it involved only direct ownership with no indirect entities or derivative securities reported, suggesting that this transaction does not reflect changes in the company's fundamentals.
- Strong Financial Performance: Tarsus Pharmaceuticals generated $451.4 million in net product sales in 2025, more than doubling from the previous year, with fourth-quarter sales reaching $151.7 million and gross margins around 93%, demonstrating robust unit economics.
- Future Growth Potential: Although the company remains unprofitable, the net loss narrowed to $66.4 million for 2025, and it ended the year with over $417 million in cash and marketable securities, providing runway for pipeline expansion, with management advancing multiple Phase 2 trials for indications like ocular rosacea and Lyme prevention.
See More
TARSUS PHARMACEUTICALS INC - QUALIFIED FOR EXTRA MILESTONES AND GRADUATED ROYALTIES FOR TP-03 IN GREATER CHINA
- Company Announcement: Tarsus Pharmaceuticals has announced eligibility for additional milestones and tiered royalties related to their product TP-03 in Greater China.
- Market Expansion: This development indicates Tarsus's strategic efforts to expand its market presence and capitalize on opportunities in the Chinese pharmaceutical sector.
See More
Tarsus Pharmaceuticals Q4 2025 Earnings Call Highlights
- Sales Performance Breakthrough: Tarsus Pharmaceuticals achieved over $450 million in net sales for 2025, successfully aiding more than 500,000 patients with Demodex blepharitis, indicating strong market demand for its product XDEMVY, which is expected to drive sustained growth for the company.
- Future Growth Potential: Management anticipates that XDEMVY's sales potential will exceed $2 billion, reflecting confidence in market penetration and the expansion of the prescriber base, strategically laying the groundwork for future revenue growth.
- R&D and Clinical Trials: Tarsus initiated the first-ever Phase II trial for TP-04 targeting ocular rosacea and plans to conduct a clinical trial for TP-05 in 2026, demonstrating the company's proactive approach to new product development and market expansion.
- Financial Outlook: The guidance for 2026 net product sales is projected between $670 million and $700 million, with annual growth exceeding $230 million, as management maintains an optimistic view on future sales growth while expecting operating expenses to remain within a reasonable range to ensure financial health.
See More
Tarsus Pharmaceuticals Reports Narrowed Losses in 2025 Financials
- Significant Sales Growth: In Q4 2025, Tarsus Pharmaceuticals reported net product sales of $151.67 million, a 128% increase from $66.41 million in the same quarter last year, indicating strong market demand for its core product XDEMVY, which significantly boosts company revenue.
- Narrowed Losses: The net loss for Q4 2025 was $8.37 million, or $0.20 per share, a substantial improvement from a loss of $23.11 million and $0.60 per share in the prior year, reflecting effective strategies in cost control and sales growth.
- Global Expansion Plans: XDEMVY is expected to receive approval for a preservative-free formulation in Europe by 2027, while its partner Grand Pharmaceutical Group Ltd. anticipates approval in Greater China by 2026, which will further enhance the company's growth potential in international markets.
- R&D Drug Progress: The company is conducting clinical trials for TP-04 and TP-05, with the former targeting ocular rosacea and the latter aimed at Lyme disease prevention, with TP-05 expected to initiate studies in Q2 2026, providing new growth opportunities for the company's future product pipeline.
See More
